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ABSTRACT: Noncovalent and electrostatic interactions facilitate the
formation of complex networks through molecular self-assembly in
biomolecules such as proteins and glycosaminoglycans. Self-assembling
peptide amphiphiles (PA) are a group of molecules that can form
nanofibrous structures and may contain bioactive epitopes to interact
specifically with target molecules. Here, we report the presentation of
cationic peptide sequences on supramolecular nanofibers formed by
self-assembling peptide amphiphiles for cooperative enhanced anti-
bacterial activity. Antibacterial properties of self-assembled peptide
nanofibers were significantly higher than soluble peptide molecules
with identical amino acid sequences, suggesting that the tandem
presentation of bioactive epitopes is important for designing new
materials for bactericidal activity. In addition, bacteria were observed to
accumulate more rapidly on peptide nanofibers compared to soluble
peptides, which may further enhance antibacterial activity by increasing the number of peptide molecules interacting with the
bacterial membrane. The cationic peptide amphiphile nanofibers were observed to attach to bacterial membranes and disrupt
their integrity. These results demonstrate that short cationic peptides show a significant improvement in antibacterial activity
when presented in the nanofiber form.
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1. INTRODUCTION
Antibiotics are commonly used for the treatment of bacterial
infections in humans and domestic animals.1,2 However,
extensive use and/or misuse of antibiotics may result in the
development of antibiotic-resistant bacteria, which currently
constitute a major health issue.3,4 The design of new antibiotics
and administration methods to prevent the evolution of
antibiotic resistance in pathogens is therefore of major interest
and importance. However, new antibiotics are not developed as
rapidly as needed, making delivery methods a greater priority
for combating antibiotic-resistant bacteria.5,6
Even though individual organisms may fail to thrive under
adverse conditions, the species as a whole may survive if a
beneficial mutation is produced in one of its members.7
Consequently, bacteria under stressful conditions downregulate
the elements of their DNA repair mechanisms to produce more
mutations, which may aid in acquiring resistance against
antibiotic pressure.8 Bacteria in their natural environment are
also exposed to uni- and multicellular competitors that produce
a series of natural antibacterial agents. These natural
antibacterial agents can keep the adaptive mechanisms of
bacteria in check through an evolutionary arms race in which
bacterial defenses to specific antibacterials are counteracted by
changes in antibacterial-producing organisms.9,10 Use of these
naturally evolved antibacterial agents is promising for develop-
ment of novel drugs against bacteria. Antimicrobial peptides
(AMPs), which are also called host defense peptides, are one of
these ancient and successful strategies that occur in both plants
and animals.11
Many of the natural AMPs are composed of short-sequences,
exhibit an amphipathic structure consisting of both hydro-
phobic and hydrophilic domains, and carry overall net positive
charges because of their lysine, arginine, and histidine
residues.12 The initial interaction of AMPs with the bacterial
membrane involves electrostatic attractions between positively
charged peptides and negatively charged membranes.13,14 This
first interaction is relatively nonspecific, as L- or D-enantiomers
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of amino acids do not change their electrostatic interaction
potential under experimental conditions.15 Following initial
attachment, some AMPs are internalized and others function
through membrane disruption. Although there are different
biophysical models to explain the behavior of AMPs against
bacterial membranes, passing a threshold concentration is
generally considered to be necessary for action,16 with cationic
AMPs usually working at higher concentrations.17 In addition,
high-molecular weight peptides have a higher potential to be
recognized and degraded by proteolytic enzymes, and the
metabolic costs of antibacterial production also increase with
protein size. Consequently, many natural antibacterials are
small cationic peptides that can be produced at high
concentrations at relatively low cost (in terms of both
metabolic investment in living systems and monetary cost in
human economics) and show greater bactericidal activity due to
their ability to escape from proteolytic degradation.18
One of the disadvantages of AMPs compared to most
antibiotic drugs is that, because of enzymatic degradation, the
half-life of AMPs is significantly shorter than most antibiotics.19
However, a multivalent display method can increase the
stability and half-life of peptides by intramolecular self-
assembly.20,21 Self-assembly is convenient for combining
different elements such as viral assembly and gene delivery
with the antimicrobial effects of host defense peptides.22
Noncovalent interactions such as van der Waals, π−π,
hydrogen bonding, and electrostatic interactions can create
molecular attractions and promote self-assembly.23 Molecular
self-assembly is used by nature for various tasks, foremost
among which is the self-assembly of peptides, proteins, and
membranes. Self-assembling peptides form into well-organized
structures through hydrophobic and hydrophilic interactions,
which improves the stability of the overall structure.24−26
Fibrous matrixes can be used as scaffold support for mammalian
cell proliferation and provide resistance against bacterial
colonization.27 Peptides with β-sheet secondary structures can
be used for biomedical purposes such as space fillers for wound
healing to prevent bacterial colonization.28 However, bacterial
cell targeting is not the only property of cationic peptides.
Translocation of phosphatidylserine and glycosylation differ-
ences cause cancer cell membranes to carry negative charges
relative to healthy cell membranes, and cationic peptides target
these membranes as in the case of bacterial membrane targeting
efforts.29 The β-sheet forming self-assembling peptide
amphiphiles contain a hydrophobic tail, which induces
formation of nanostructures through hydrophobic interactions
in aqueous media, a β-sheet forming sequence, which is
responsible for intermolecular hydrogen bonding, a hydrophilic
sequence, which increases solubility of the individual molecules
in water, and possible bioactive epitopes, which depend on the
intended target of the peptide amphiphile molecule.30−32
Here, we demonstrate that the multivalent presentation of
antibacterial peptides on self-assembled supramolecular nano-
fibers provides significant improvements in the context of
antibacterial activity compared to single, soluble peptides.
Antibacterial peptide nanofibers affect both Gram-positive and
Gram-negative bacteria with improved antibacterial activity. In
addition, while most natural linear amphipathic antimicrobial
peptides form α-helices when they bind to bacterial
membranes, our design forms an amphipathic β-sheet structure.
Therefore, this work provides additional information on the
dynamics of β-sheet forming AMPs.33,34
2. EXPERIMENTAL SECTION
2.1. Materials. 9-Fluorenylmethoxycarbonyl (Fmoc) and
tert-butoxycarbonyl (Boc) protected L-amino acids, lauric acid,
Rink amide MBHA resin, and uronium hexafluorophosphate
(HBTU) were purchased from NovaBiochem. N,N-Diisopro-
pylethylamine (DIEA), dichloromethane (DCM), dimethylfor-
mamide (DMF), trifluoroacetic acid (TFA), fluorescein
isothiocyanate isomer I (FITC), and all other chemicals used
in peptide synthesis and material characterization were
purchased from Merck, Fisher, Alfa Aesar, and Sigma-Aldrich.
Live/Dead BacLight bacterial viability kit L-7012 was purchased
from Life Technologies. Luria−Bertani bacterial culture
medium was purchased from Merck, and LB broth with agar
was purchased from Sigma. Calcein-AM and other cell culture
materials were purchased from Invitrogen. Other chemicals and
materials were purchased from either Sigma-Aldrich or Thermo
Scientific. All chemicals and solvents used in this study were
analytical grade.
2.2. Peptide Synthesis, Purification, and Character-
ization. Cationic antibacterial peptide amphiphile lauryl-
VVAGKKKGRW-Am and cationic antibacterial soluble peptide
Ac-KKKGRW-Am were synthesized on Rink amide MBHA
resin (0.46 mmol g−1). Amino acid couplings were performed
with 2:1.95:3 equiv of Fmoc-protected amino acid, HBTU, and
N,N-diisopropylethylamine (DIEA), respectively, in dimethyl-
formamide (DMF) for 5 h. Twenty percent piperidine/DMF
solution was used for 25 min to remove Fmoc protecting
groups. A mixture of trifluoroacetic acid (TFA), triisopropylsi-
lane (TIS) , and water (95:2.5:2.5 ratio, respectively) was used
for cleavage of the peptides from the resin for 2 h. Excess TFA
was removed by rotary evaporation. The remaining viscous
peptide solution was treated with ice-cold diethyl ether at −20
°C, and the resulting white pellet was freeze-dried. The
peptides were identified and analyzed by reverse phase high
performance liquid chromatography (HPLC) on an Agilent
6530 accurate-mass Q-TOF liquid chromatography/mass
spectrometry (LC/MS) equipped with an Agilent 1200
HPLC. A Phenomenex Luna 3 μ C8 100A (50 × 3.00 mm)
column was used as the stationary phase, and a water/
acetonitrile gradient with 0.1% formic acid was used as the
mobile phase to identify the peptides. Peptides were purified by
using a 1200 Agilent HPLC with a Zorbax 300SB C8 4.6 100
mm column and a water/acetonitrile (0.1% TFA) gradient.
Then, peptides were treated with HCl solution to exchange the
trifluoroacetate salt.
2.3. Circular Dichroism (CD) Spectroscopy. CD spectra
were recorded using a J-815 Jasco spectrophotometer at room
temperature under a constant flow of nitrogen gas. Aqueous
solutions (125 μM) were diluted from 2 mM stock solutions of
peptides. CD spectra were obtained at pH 7.4 within the data
interval of 300 to 190 nm−1, with a bandwidth of 1.0 nm, and a
scanning speed of 500 nm min−1. Scans were repeated three
times and averaged. The results were converted to molar
ellipticity per amino acid residue. To evaluate the effects of pH
on secondary structure, the peptide amphiphile solution was
prepared at pH 7.4, and its pH was adjusted to pH 6.5 from the
fiber-making peptide amphiphile stock solution at pH 7.4.
2.4. Transmission Electron Microscopy. The peptide
amphiphile solution was diluted from 2 mM stock solution into
125 μM at pH 7.4 for sample preparation. Peptide nanofibers
were placed on a transmission electron microscopy grid. After 7
min of incubation, uranyl acetate (2 wt %) staining was
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performed for 1 min. A FEI Tecnai G2 F30 transmission
electron microscope was used at 200 kV for imaging. Soluble
peptide solution was also diluted from 2 mM stock solution
into 1000 μM for transmission electron microscopy character-
ization.
2.5. Antibacterial Activity Analysis. The antibacterial
activity of both peptides and their minimum inhibitory
concentrations (MICs) were assessed by Live/Dead analysis.
A survival assay for both Escherichia coli and Bacillus subtilis
bacteria was also used to compare the efficiencies of nanofiber
structures and soluble peptides.
2.6. Minimum Inhibitory Concentration of Peptides.
Escherichia coli (RSHM 888, National Type Culture Collection
Laboratory, Ankara, Turkey)35,36 was used as a model system
for Gram-negative bacteria, while Bacillus subtilis (ATCC 6633)
was used as a model system for Gram-positive bacteria. Bacteria
were cultured at 37 °C in a shaking incubator at 200 rpm for 14
h to achieve mid logarithmic growth phase. Luria−Bertani (LB)
culture medium was used for bacterial growth, and broth
dilution was performed after bacteria reached mid logarithmic
growth phase. Both bacteria were diluted to 5 × 106 CFU mL−1
using fresh LB for minimum inhibitory concentration experi-
ments. Bacterial CFU numbers were checked by both broth
dilution and agar plate colony counting. OD600 = 0.1, as
measured by M5 microplate reader (Molecular Devices), was
accepted to be 107−108 CFU mL−1 of bacteria as per
McFarland Standard No. 1, and 5 × 105 CFU mL−1 of bacteria
were used in minimum inhibitory concentration experiments.
Bacteria (100 μL, 106 CFU mL−1) in LB were added into 100
μL of peptide solution in 1× PBS (peptides were prepared in
96-well plate 1 h prior to addition). After incubating for 18 h in
a shaking incubator at 37 °C, 20 μL from each sample was
seeded onto agar plates. Minimum inhibitory concentrations
were measured as the lowest peptide concentration that inhibits
bacterial growth. Bacterial cells in 100 μL of LB and 100 μL of
1× PBS mixture without peptides were used as positive control.
For each concentration of peptides, three replicates were used.
2.7. Live/Dead Assay for Bacteria. A bacterial viability kit,
containing SYTO9 for staining living bacterial cells and
propidium iodide for staining dead bacterial cells, was used to
evaluate bacterial cell viability in the presence of bioactive
peptides. Six micromolar SYTO9 and 30 μM propidium iodide
were mixed in 1× PBS solution and used to fix previously
prepared bacteria−peptide mixtures for 15 min in dark at room
temperature. Five microliters of samples from each group were
visualized with a Zeiss LSM 510 laser scanning confocal
microscope. Excitation/emission values of the dyes are SYTO9,
480/500 nm, and propidium iodide, 490/635 nm.
2.8. Time-Kill Assay. Time-kill assay was performed with
both peptide nanofiber- and soluble peptide-treated bacteria at
each peptide’s minimum inhibitory concentration. Ten micro-
liters of samples were taken at 1, 6, and 24 h and incubated at
37 °C on agar plates. Number of bacteria prior to peptide
addition was used for calculating % survival rate.
2.9. Biocompatibility of Peptides for Mammalian
Cells. Human umbilical vein endothelial cell (HUVEC) line
was used in order to check the cytotoxicity of the peptides by
Live/Dead assay (Invitrogen). HUVECs were donated by
Yeditepe University, Istanbul, Turkey. Peptide solutions (100
μL) in 1× PBS were mixed with 5000 cells/well in 96-well
plates. After 24 h of incubation, the medium was discarded and
wells were washed with 1× PBS. Then, wells were incubated
with 2 μM calcein-AM and 2 μM EthD-1 in PBS for 30 min at
room temperature. Three random images were taken for every
well under a Zeiss, Axio Scope A1 fluorescence microscope at
10× magnification. ImageJ software was used for counting.
2.10. Visualization of Peptide Nanofibers by Confocal
Microscopy. The peptide amphiphile stock solution was
prepared at 2 mM. After 1 h of incubation at room temperature,
FITC tagged peptide amphiphiles were mixed at a 5% ratio into
the antibacterial peptide amphiphile solution37−39 as we used
previously.40 Bacteria were incubated with the peptide solution
for 30 min at 37 °C in a shaker incubator. Following peptide
exposure, 5 μL of samples were transferred between glass
coverslips for imaging under a Zeiss LSM 510 laser scanning
confocal microscope. FITC configurations were 488 nm
excitation laser/505−530 nm emission filter.
2.11. Analyses of Morphological Changes of Bacteria
by Scanning Electron Microscopy Imaging. A FEI Quanta
200 FEG scanning electron microscope with an ETD detector
was used in order to visualize the morphological changes
caused by both soluble peptides and peptide nanofibers on
bacterial membranes. Bacterial cells were fixed with 2.5%
glutaraldehyde in PBS for 1 h. Samples were then postfixed
with 1% osmium tetroxide for 1 h and dehydrated in a series of
20%, 40%, 60%, 80%, and 100% EtOH for 2 min per step. After
the final 100% EtOH step, the samples were kept in fresh 100%
EtOH for at least 1 h.
2.12. Analysis of Morphological Changes of Bacteria
by Atomic Force Microscopy Imaging in Aqueous
Environment. Mica surfaces were coated with gelatin in
order to immobilize living bacteria for acquiring AFM images in
liquid.41 All AFM imaging experiments were performed in
aqueous environment. Bacterial culture (150−200 μL) was first
dropped on a cleaved coated mica surface and waited 5−10
min. Then, equal volume of peptide amphiphile solution or
soluble peptide solution was added onto the bacterial cells. A
total of 300−400 μL of sample volume were imaged using an
Asylum Research MFP-3D atomic force microscope under
tapping mode. Soft silicon nitride tips with nominal spring
constants of 0.05 N/m were used for imaging. Atomic force
micrographs were taken at a resolution of 512 × 512 pixels or
1024 × 1024 pixels.
2.13. Statistical Analysis. Results are expressed as mean ±
standard deviation or with 95% confidence intervals. One-way
analysis of variance (ANOVA) with Tukey’s Multiple
Comparison Test (GraphPad Prism v5) was used to compare
values between the experimental groups (Figure 3d). p ≤ 0.05
was considered as statistically significant. In Graphpad Prism,
D’Agostino−Pearson, Shapiro−Wilk, and Kolmogorov−Smir-
nov normality tests were used to test if the values are from a
Gaussian distribution.
3. RESULTS
The self-assembling peptide lauryl-VVAGKKKGRW-Am and
soluble peptide Ac-KKKGRW-Am were synthesized using
Fmoc solid phase peptide synthesis method to compare the
antibacterial activity of soluble and nanofibrous peptides on
Gram-positive B. subtilis and Gram-negative E. coli. This
sequence was chosen due to previous results in the
antimicrobial effect of the arginine-tryptophan couple42,43 and
our results on multiple lysine-carrying sequences for anti-
bacterial activity (Figure S4). In Ac-KKKGRW-Am peptide, the
free alpha amine is acetylated to prevent the inclusion of an
additional charged group in the sequence and limit the
interaction of the peptide with other molecules. Both peptides
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(Figure 1a,b) exhibit a potential antimicrobial sequence
through their lysine, arginine, and tryptophan residues;
however, the soluble peptide (Figure 1b) lacks the hydrophobic
alkyl tail or the β-sheet forming VVA sequence. The peptides
were purified and characterized by LC/MS (Figure S1a,b).
Transmission electron microscopy was also used to visualize
the general morphology of both peptides. Peptide amphiphiles
were observed in a nanofiber morphology (Figure 1c), while
aggregate formation was not observed for the soluble peptide
(Figure S2).
In CD measurements, the peptide amphiphile molecules
exhibited a local maximum peak around 200 nm and a local
minimum peak around 220 nm and demonstrated a
predominantly β-sheet structure, whereas the soluble peptide
exhibited a local minimum peak around 195 nm and
demonstrated a predominantly random-coil structure (Figure
1d). CD spectra were also acquired at different pH values to
determine the pH at which the nanofiber morphology is
disrupted, and the β-sheet morphology was found to be present
at pH 7.4 but not pH 6.5 (Figure S6). For this experiment, the
Figure 1. Chemical representation of the peptide amphiphile lauryl-VVAGKKKGRW-Am (a) and single peptide Ac-KKKGRW-Am (b).
Transmission electron microscopy image of peptide amphiphiles (c) following their self-assembly into supramolecular nanofibers, in contrast to
soluble peptides showing no nanofiber formation (Figure S2). (d) CD spectra of both peptides.
Figure 2. Minimum inhibitory concentrations of both peptides (a). Time-kill assay of bacteria by peptides (b). Error bars represent standard
deviation, n = 3. E. coli and B. subtilis cells stained with Baclight live/dead bacterial viability kit (c−e).
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pH 6.5 sample was prepared from the fiber-making stock
solution at pH 7.4.
Minimum inhibitory concentrations of both peptides were
determined against both Gram-positive and Gram-negative
bacteria by broth dilution and colony forming unit (CFU)
counting methods. Briefly, peptides were serially diluted in 1×
PBS solutions and mixed with equal volume of bacteria in fresh
LB prior to counting assays. Inhibitory concentrations of
peptides against Gram-negative (E. coli) and Gram-positive (B.
subtilis) bacteria are shown in Figure 2a. Half serial dilutions of
peptides were prepared from 2 mM stock solutions, and the
lowest dilution that was sufficient to kill all bacteria in agar
plates was considered to be the minimum inhibitory
concentration. As shown in Figure 2a, the antibacterial peptide
nanofibers were 4−8 times more effective than their
antibacterial soluble peptide counterparts in terms of
concentration values. The nanofiber form of the antibacterial
peptides was therefore found to be much more effective for
bactericidal activity compared to presentation of otherwise
identical sequences in solution.
To compare the rate of antibacterial action, a time-kill assay
was performed by taking 10 μL from both peptide nanofiber-
treated and soluble peptide-treated groups at 1, 6, and 24 h
time points. Both peptides were used at their minimum
inhibitory concentrations for this experiment. Incubation and
CFU counting showed that, while soluble peptide killed around
20% of bacteria, peptide nanofibers killed around 80% after 1 h
of incubation (Figure 2b).
BacLight bacterial live/dead kit, containing the nucleic acid
stains Syto-9 and PI, was used to visualize bacterial survival
after 1 h of incubation.44 After 1 h of bacterial incubation with
peptide nanofibers or soluble peptides, both cationic peptide
systems were observed to kill bacteria in their effective
concentrations (as determined by minimum inhibitory
concentration results) (Figure 2c,d). Staining also confirmed
the difference between the live/dead ratios of peptide
nanofiber-treated and soluble peptide-treated groups with
respect to bactericidal activity.
Biocompatibility of both peptides with mammalian cells was
investigated using HUVECs. These cells are frequently used as
models for endothelial cells, which are the first cells
encountered by antimicrobial agents that are administered
intravenously.45 Even though the survival of peptide nanofiber-
treated HUVECs was significantly lower than that of soluble
peptide-treated cells, biocompatibility of the peptide nanofiber
was within an acceptable range compared to tissue culture plate
control (Figure 3).
Visualization of peptide nanofibers on bacteria was
performed by confocal microscopy. A mixture of fluorescently
labeled peptide amphiphile molecules (FITC-PA) and non-
fluorescent antibacterial peptide amphiphile molecules created
peptide nanofibers that could be detected on both Gram-
positive and -negative bacteria after 10 min of incubation
(Figure S5). The images (Figure 4a−d) show fluorescence
spreading throughout the bacterial cells, which suggests the
internalization of FITC labeled peptides into the cytoplasm of
both bacteria.46 Time-lapsed imaging was also performed using
peptide nanofibers (5% FITC) (Figure 4e). The first image (0
s) was taken 40 s after the addition of fluorescently labeled
nanofibers. These results show the rapid binding of peptide
nanofibers to bacterial membranes.
Figure 3. Fluorescent images of HUVECs with peptide nanofibers (a), with soluble peptides (b), and without any peptide treatment (tissue culture
plate control) (c) after 24 h of incubation using live/dead assay. Cytotoxicity of peptides on HUVECs (d).
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Antibacterial peptide nanofiber- and soluble peptide-treated
bacteria were visualized by both atomic force microscopy and
scanning electron microscopy in order to determine the
morphological effects of peptide treatment on bacterial cells.
In the self-assembling peptide-treated group, peptide nanofibers
were observed to be distributed evenly across the mica surface
(Figure 5a,b), which is potentially beneficial for antimicrobial
applications of the peptide system on catheters and other
biofilm-prone surfaces, as these nanofibrous structures
exhibited a dense network formation that may protect a large
area against bacterial entry. However, consistent with TEM
results, no nanofibers were observed in the soluble peptide-
treated group (Figure 5c). After encountering the bacterial
membrane, peptide nanofibers are expected to penetrate inside
the membrane structure through hydrophobic interactions.
After 1 h of incubation of peptides with bacteria, distinct
circular areas around clustered bacteria can be observed (Figure
5a), and phase differences in these areas suggest that bacteria
were losing cytoplasmic fluid to the environment, which is
consistent with our observations. In addition, sequential
measurement of nanofiber-treated samples showed increased
nanofiber length (Figure 5d). Higher-magnification atomic
force microscopy images of bacteria (Figure 5e) showed
disruptions in bacterial membranes, especially for nanofiber-
treated groups in phase images. Both groups were treated with
minimum inhibitory concentrations (125 μM for nanofiber, 1
mM for soluble peptide), and atomic force microscopy images
were taken after 10 min of interaction in water.
E. coli cells were also fixed with 2.5% glutaraldehyde for 60
min for the scanning electron microscopy characterization of
cell−nanofiber interactions. In both scanning electron micros-
copy and atomic force microscopy results, nanofiber treatment
was found to be associated with strong disruption of bacterial
membranes (Figure 5). Destabilized, disrupted membranes and
shrunken bacterial morphologies exhibiting nonstandard
behavior were also observed under peptide nanofiber treatment.
In addition, clear membrane ruptures (Figure 5f) can be
observed for the soluble peptide-treated group.
4. DISCUSSION
There are several concepts for the mode-of-action of
antimicrobial peptides.47 The self-assembly method can be
utilized to develop multivalent peptide systems for antimicro-
bial activity by disrupting bacterial membrane.48 Here, we
Figure 4. Confocal microscopy images of peptide nanofibers and E. coli RSHM 888 (a,c) and B. subtilis ATCC 6633 (b,d). Snapshots show fast
membrane binding of nanofibers (e).
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exploited soluble Ac-KKKGRW-Am peptide, which shows
antibacterial activity in high doses. The self-assembly of peptide
amphiphiles is known to provide supramolecular amphipathic-
ity to peptide networks and potentially create a charge-density
in the periphery of the nanofibers, which is a driving force for
improved antibacterial activity. Xu et al. previously reported
that D-amino acid substitution in peptides can improve
antimicrobial activity despite reducing nanofiber integrity.49
Therefore, the self-assembly might produce a greater
antimicrobial effect by simply accumulating the individual
peptide units and then promoting membrane disruption by
disassembled monomers when a local threshold concentration
is obtained.
Increasing peptide nanofiber concentration was observed to
be associated with bacterial cell accumulations under live/dead
analysis (Figure 2e). This might suggest that, unlike soluble
peptide molecules, the mesh-like network produced by the self-
assembling PA system may also allow the filtering of bacterial
cells from liquid environments through membrane−peptide
interactions.
Mammalian cells are expected to be resistant to the proposed
charge interaction of the peptide system, as their membranes
exhibit a zwitterionic nature and contain phosphatidylcholine,
sphingomyelin, and phosphatidylserine phospholipids. Never-
theless, AMPs with strongly hydrophobic character can interact
with phosphatidylcholine found in the mammalian cellular
membrane and affect membrane integrity.50 Therefore, nano-
fiber aggregates with strong hydrophobicity slightly affected the
mammalian cells.
Atomic force microscopy and scanning electron microscopy
results demonstrated that membrane destabilization is the
mode of action for both peptides. Both peptides potentially
targeted bacterial membranes. This specific targeting effect may
derive from the cationic amino acids in the peptide sequences
and the penetrating ability of the hydrophobic tryptophan
residue into bacterial membranes, which have previously been
suggested in the literature. Consistent with the survival data,
atomic force microscopy and scanning electron microscopy
results suggest faster bacterial membrane destabilization for
peptide nanofiber-treated groups compared to soluble peptide-
treated groups for both Gram-positive and Gram-negative
bacterial samples.
Figure 5. Cell membrane disruption induced by antibacterial peptides. Atomic force microscopy images were obtained in water under tapping mode.
AFM phase image of nanofiber-treated B. subtilis cells (a) following 1 h of incubation, phase image of nanofiber-treated E. coli cells (b), phase image
of soluble peptide-treated E. coli cells (c), flattened phase images of peptide nanofiber-treated E. coli cells (d), higher-magnification images (e), and
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5. CONCLUSION
While research in antimicrobial peptides has been advancing
rapidly, β-sheet containing AMP studies are still rare. This work
focuses on the multivalent presentation of antimicrobial
peptides on peptide nanofibers and provides additional
information on the dynamics of β-sheet forming AMPs. A
short-sequenced peptide amphiphile molecule was used against
E. coli and B. subtilis. Short sequence peptides with lower
molecular masses are less immunogenic, and this could be
beneficial for the practical applications of AMPs against
pathogens. Peptide amphiphile molecules create positively
charged clusters at the nanofiber periphery, which may increase
their effective molarity compared to soluble peptide mole-
cules.51 We observed antibacterial effects of peptide amphi-
philes against both Gram-positive and Gram-negative bacteria.
Since both bacteria were affected similarly, the sequence is
considered to have broad-spectrum activity against bacteria.
While the cationic interactions cause destabilization of bacterial
membranes, the higher hydrophobicity of the peptide network
system is detrimental to mammalian cell membranes due to
peptide−zwitterionic phospholipid interactions. However, the
antibacterial activity of the peptide system was improved eight
times under the nanofiber configuration, while the associated
cytotoxicity was still not significant. FITC-tagged localization
results showed the fast accumulation of peptide nanofibers on
bacteria, which is an important parameter due to the necessity
of cell−peptide associations for membrane disruption and
penetration. Peptide nanofibers were also observed to be
directly associated with bacteria. The nanofiber network of
cationic AMPs was observed to attach to the bacterial
membranes and actively disrupt them. While it is uncertain
whether the soluble AMPs also function in a similar way, they
have also facilitated the destabilization of bacterial membranes.
Overall, our findings support the improvement of antibacterial
activity of short cationic peptides when presented in the
nanofiber form. In addition, β-sheet structure and molecular
interactions of peptide amphiphiles create a more stable
cationic AMP for use in therapeutic applications. Furthermore,
length-dependent effects of the RW combination have been
previously shown in the literature.42 Consequently, the cationic
sequences described in the present study can be repeated to
increase the positive charge and modulate the balance of
hydrophobic and hydrophilic residues to promote antibacterial
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